首页> 外文OA文献 >Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

【2h】

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

机译：高风疹骨髓增生综合征和急性髓性白血病患者的序贯氮杂氨胺：单臂，第1/2期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Courtney D DiNardo; Naval Daver; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Marina Konopleva; Naveen Pemmaraju; Hui Yang; Sherry Pierce; William Wierda; Carlos Bueso-Ramos; Keyur P Patel; Jorge E Cortes; Farhad Ravandi; Hagop M Kantarjian; Guillermo Garcia-Manero;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. [J] . van der Helm LH, Alhan C, Wijermans PW, British Journal of Haematology . 2011,第5期

机译：在阿扎胞苷同情患者计划中，第一个阿扎胞苷周期后的血小板加倍是骨髓增生异常综合症（MDS），慢性粒细胞单核细胞白血病（CMML）和急性髓性白血病（AML）患者反应的有希望的预测指标。
2. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme [J] . Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans, British Journal of Haematology . 2011,第5期

机译：在阿扎胞苷同情患者命名的患者计划中，首个阿扎胞苷周期后的血小板加倍是骨髓增生异常综合征（MDS），慢性粒细胞单核细胞白血病（CMML）和急性髓细胞性白血病（AML）患者反应的有希望的预测指标
3. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome [J] . Narayan Rupa, Garcia Jacqueline S., Percival Mary-Elizabeth M., Leukemia and lymphoma . 2016,第3期

机译：顺序治疗的阿扎胞苷加来那度胺在先前治疗过的急性髓细胞白血病和高危骨髓增生异常综合征的老年患者中
4. Ras gene mutation in acute myeloid leukemia and Myelodysplastic syndromes: a meta-analysis of its occurrence and prognostic relevance [C] . Cheng Jingru, Wang Peng, Zhang Tai, International Conference on Advanced Materials and Computer Science . 2016

机译：RAS基因突变在急性髓性白血病和髓细胞增强综合征中：荟萃分析其发生和预后相关性
5. Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level [D] . Chen, Jiahao. 2018

机译：在干细胞水平上骨髓增生异常综合征进展为急性髓细胞性白血病
6. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm phase 1/2 study [O] . Courtney D DiNardo, Naval Daver, Elias Jabbour, -1

机译：高危骨髓增生异常综合症和急性髓细胞性白血病患者的序贯阿扎胞苷和来那度胺：单臂1/2期研究
7. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey [O] . Beguin, Yves, Selleslag, Dominik, Meers, Stef, 2015

机译：阿扎胞苷在比利时高危骨髓增生异常综合症，急性髓细胞性白血病或慢性粒细胞单核细胞白血病患者中的安全性和有效性：真实，非干预的上市后调查结果

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

著录项

引文网络

相似文献

相关主题

期刊订阅